Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | S095035 + TNG462 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| S095035 | S 095035|S-095035 | S095035 inhibits MAT2A, which potentially decreases proliferation in MTAP-deficient tumor cells (NCI Drug Dictionary). | ||
| TNG462 | TNG 462|TNG-462 | PRMT5 Inhibitor 21 | TNG462 is a PRMT5 inhibitor with selectivity for MTAP-deleted cells, which may decrease tumor growth (European J Cancer 174, 2022 (suppl 1, S84)). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06188702 | Phase Ib/II | S095035 S095035 + TNG462 | S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP | Recruiting | USA | ITA | FRA | ESP | DNK | DEU | AUS | 1 |